Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Early results support a fully-powered trial of 18F-PSMA PET/CT for prostate cancer detection, according to the investigators. PSMA-PET/CT with the radiotracer 18F-DCFPyl (18 F-PSMA PET/CT) may improve ...

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...

This trial is looking at whether doctors can use PSMA PET-CT scans to guide treatment for people who have high risk prostate cancer.

Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...

Advances in radiotherapy are rapidly transforming how prostate cancer is treated, offering patients more precise, less invasive options that can fit more easily around everyday life ...

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...